A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer

Trial Profile

A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase 0

Latest Information Update: 15 Dec 2014

At a glance

  • Drugs Sonidegib (Primary)
  • Indications Pancreatic cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Dec 2014 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 05 May 2014 Planned end date changed from 1 Nov 2014 to 1 Nov 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top